Clinical Trials Logo

Filter by:
NCT ID: NCT05604742 Withdrawn - cGVHD Clinical Trials

Belimumab for Treatment of cGVHD Following Allo-HCT

Start date: January 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Given the role of B cells in the pathophysiology of chronic graft versus host disease (GvHD), the association between elevated BAFF levels post-transplant in abnormal B-cell homeostasis and chronic GvHD, and the efficacy of belimumab in the inhibition of soluble human B lymphocyte stimulator protein (BAFF) signaling, these proof-of-principle findings support the rational for use of belimumab as treatment of chronic GvHD.The investigators propose a pilot and feasibility study to assess the safety and tolerability, as well as preliminary efficacy, of belimumab a treatment of cGvHD following allogeneic hematopoietic cell transplantation (alloHCT). The investigators' central hypothesis is that belimumab will be well tolerated and have a favorable effect on chronic GvHD,and we explored therapeutic dosage of belimumab.

NCT ID: NCT05592197 Withdrawn - Clinical trials for Advanced Hepatocellular Carcinoma

Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT

Start date: October 1, 2018
Phase: N/A
Study type: Interventional

This is a multicentri prospective cohort study to investigate the safety and efficacy of external beam radiation (RT) combined with transarterial chemoembolization (TACE) and lenvatinib vs TACE and lenvatinib in the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).

NCT ID: NCT05587881 Withdrawn - Clinical trials for Hematologic Diseases

Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation

Start date: January 1, 2022
Phase:
Study type: Observational

Aim of this study will evaluate the Impact of Covid-19 vaccine on Safety and Efficacy of Hematological Patients Received Allogeneic Hematopoietic Stem Cell Transplantation.

NCT ID: NCT05581927 Withdrawn - Brain Injury Clinical Trials

Whole-Body Hypothermia for Neonates With Hypoxic-Ischemic Encephalopathy(HIE)

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

Among term infants, hypoxic-ischemic encephalopathy due to acute perinatal asphyxia remains an important cause of brain injury in childhood. Infants with moderate encephalopathy have a 10 percent risk of death, and those who survive have a 30 percent risk of disabilities. Sixty percent of infants with severe encephalopathy die, and many, if not all, survivors are disabled. Whole-body hypothermia reduces the risk of death or disability in infants with moderate or severe hypoxic-ischemic encephalopathy.

NCT ID: NCT05578183 Withdrawn - Stroke Clinical Trials

Therapeutic Effect of Transcranial Magnetic Stimulation on Memory Impairment in Patients After Stroke

Start date: December 31, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the therapeutic effect of theta burst stimulation (TBS), which is one of stimulus pattern of repetitive transcranial magnetic stimulation, in patients with post stroke cognition impairment (PSCI). The main questions it aims to answer are: 1. To explore the therapeutic effect of TBS to patients with PSCI. 2. To compare effect of TBS with different dose. 3. To explore the mechanism of TBS by functional magnetic resonance imaging (fMRI). Participants will be asked to do: 1. Treated with TBS and cognitive training for 3 weeks (15 days). 2. Assessed with several scales, including Mini-mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Loewenstein Occupational Therapy Cognitive Assessment (LOTCA), Wechsler Adult Intelligence Scale-revised in China (WAIS-RC), Wechsler Memory Scale (WMS) before and after treatment. 3. Perform the resting fMRI, electroencephalogram (EEG) and event related potential before and after treatment. Researchers will compare high-dose group, low-dose group and sham group to see if TBS play a role in PSCI and if the effect of high dose TBS was stronger than low dose.

NCT ID: NCT05575245 Withdrawn - Atherosclerosis Clinical Trials

Clinical Of Drug-eluting Stent Versus Excimer Laser Ablation Combined Drug-coated Balloon To Treat Arteriosclerosis Occlusive Disease Of Lower Extremity

Start date: March 3, 2022
Phase: N/A
Study type: Interventional

This is a Prospective randomized controlled study to evaluate the difference of safety,effectiveness between Excimer Laser Ablation Combined Drug-coated Balloon and drug-eluting stent in treatment of femoral-popliteal artery lesions.

NCT ID: NCT05571540 Withdrawn - Clinical trials for B-cell Acute Lymphoblastic Leukemia

Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

Start date: October 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, single-center, open-labeled clinical study to evaluate the safety and efficacy of LstCAR019 injection for patients with relapsed/refractory(r/r) B-cell Acute Lymphoblastic Leukemia(B-ALL).

NCT ID: NCT05570188 Withdrawn - B-cell Lymphoma Clinical Trials

Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

Start date: October 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-CD19 U-CAR-NK Cells Therapy combined with HSCT for B cell hematologic malignancies.

NCT ID: NCT05531708 Withdrawn - Clinical trials for Mesothelin-positive Advanced Refractory Solid Tumors

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Start date: April 2, 2021
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of novel Mesothelin CAR-T in patients with Mesothelin-positive advanced refractory solid tumors.

NCT ID: NCT05529875 Withdrawn - Quality of Recovery Clinical Trials

Comparison of Propofol and Sevoflurane Anesthesia on the Quality of Recovery After Ambulatory Surgery in Obese Patients

Start date: October 2022
Phase: N/A
Study type: Interventional

This study was designed to compare propofol intravenous anesthesia to sevoflurane inhalation anesthesia on the quality of recovery after surgery for anal fistula in obese patients. Propofol-based total intravenous anesthesia (TIVA) and sevoflurane inhalation anesthesia are the two main anesthesia techniques. Obesity influences not only anesthetics metabolic but also physical function of patients, so it is meaningful to study which anesthesia technique is better for the recovery of obese patients after surgery.